Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Equity (2016 - 2025)

Ultragenyx Pharmaceutical has reported Return on Equity over the past 10 years, most recently at 0.16% for Q4 2025.

  • Quarterly Return on Equity rose 18.0% to 0.16% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.16% through Dec 2025, up 18.0% year-over-year, with the annual reading at 0.07% for FY2025, 4.0% down from the prior year.
  • Return on Equity was 0.16% for Q4 2025 at Ultragenyx Pharmaceutical, up from 0.07% in the prior quarter.
  • Over five years, Return on Equity peaked at 0.16% in Q4 2025 and troughed at 0.08% in Q3 2023.
  • The 5-year median for Return on Equity is 0.0% (2021), against an average of 0.01%.
  • Year-over-year, Return on Equity decreased -8bps in 2023 and then grew 18bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.0% in 2021, then tumbled by -124497bps to 0.02% in 2022, then surged by 101bps to 0.0% in 2023, then plummeted by -14625bps to 0.02% in 2024, then soared by 957bps to 0.16% in 2025.
  • Per Business Quant, the three most recent readings for RARE's Return on Equity are 0.16% (Q4 2025), 0.07% (Q3 2025), and 0.04% (Q2 2025).